Two new Swiss developed drugs designed to treat coronavirus are on the verge of being approved by regulators around the world.
A biotech company in Ticino, Humab, is developing an antibody treatment which is showing in trials an 85% cut in hospitalizations and deaths and a drug developed by a Zurich company, Molecular Partners, uses proteins to fight the infection.
Both trials are well advanced and there are hopes the Ticino treatment will get approval in the United States within days and the European Medicines Agency is also evaluating the results.
Dominique Braun, an infection expert at the University Hospital Zurich, says the treatments are important as not everyone will be vaccinated and it remains uncertain how well the vaccines will work against new strains.
Geneva could foot the G7 bill
US NGO discovers Swiss child abuse cases
French singer banned by Paleo
Cars going uninspected
War may lead to rent rises
Not a heatwave, yet
